A Prospective Observational Study to Evaluate Quality of Life and Costs in a Real Life Setting in Patients Treated With 90Y-Zevalin
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Lymphoma, Follicular, Non-Hodgkin Lymphoma
Both
Lymphoma, Follicular, Non-Hodgkin Lymphoma
Trial Information
A Prospective Observational Study to Evaluate Quality of Life and Costs in a Real Life Setting in Patients Treated With 90Y-Zevalin
Inclusion Criteria:
- Advanced cancer of the lymph nodes of follicular type at study inclusion
- The patient has relapsed or has refractory disease, after previous treatment with
rituximab
- Treating physician has decided to treat the patient with a 90Y-Zevalin regimen
- The patient is >= 18 years of age
- Patient has given informed consent
Exclusion Criteria:
- Patient is unwilling or unable to give informed consent
- Patient is participating in another clinical trial
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
The medical resources consumed due to hematological adverse events that occurred following treatment with 90Y-Zevalin treatment
Outcome Time Frame:
one year after inclusion
Safety Issue:
No
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Belgium: Federal Agency for Medicinal Products and Health Products
Study ID:
13455
NCT ID:
NCT01164696
Start Date:
August 2007
Completion Date:
May 2009
Related Keywords:
- Lymphoma, Follicular
- Non-Hodgkin Lymphoma
- Quality of Life, Health Care Costs
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
Name | Location |
|---|
